



The  
Precision  
Peptide  
Company

# Precision. *Elevated.*

Engineering the next generation of human performance.

**CSE: BPC | OTCQB: PNGAF**

*May 2026*

# A massive shift is happening in human health.

Peptides are rapidly transitioning from **niche clinical therapeutics** to **mainstream consumer staples**.

- **The Longevity Movement:** Consumers are actively investing in preventative healthspan extension.
- **The GLP-1 Wave:** Ozempic® and Wegovy® have globally validated and normalized peptide therapies.
- **Optimization Narratives:** High-profile platforms (Joe Rogan, HIMS) are driving unprecedented top-of-funnel awareness.



# Demand is growing. But the delivery is **broken**.

The industry relies on outdated, high-friction paradigms that fundamentally prevent mass consumer adoption.



**Invasive Injections:** Painful, intimidating, and non-compliant for daily over-the-counter use.



**Compounding Logistics:** High barrier to entry, inconsistent molecular quality, and regulatory grey areas.



**Cold Storage:** Fragile compounds that limit mobility and seamless lifestyle integration.


*The market exists. The delivery mechanism **hasn't caught up**.*




03 // THE BREAKTHROUGH

We extract the power of clinical-grade peptides and engineer them into **frictionless, consumer ready formats.**

**No needles. No mixing.**  
**Just apply.**



# Proprietary Transdermal Delivery\*



A first-of-its-kind continuous delivery matrix designed to replace subcutaneous injections.

**PHASE 1**  
Stabilization

Active peptide compounds are suspended in a temperature-stable matrix, eliminating cold-storage requirements.

**PHASE 2**  
Permeation

Advanced absorption enhancers temporarily modify the stratum corneum, allowing large molecules to enter the bloodstream.

**PHASE 3**  
Sustained Release

Controlled, micro-dosed delivery over extended hours significantly improves half-life and biological bioavailability.

*We don't just sell molecules  
- we own the delivery layer.*

\*Transdermal Patch Currently Under Development

# First to Market Consumer Portfolio

A full-stack, targeted wellness line currently being developed on our delivery architecture, bypassing clinical friction.



BPC-157 API

## Recovery

Accelerated tissue repair, joint recovery, and systemic.

NOOTROPIC API

## Cognitive

Sustained focus, mental clarity, and neuro-protective stress reduction.

NAD+ / PEPTIDES

## Longevity

Cellular optimization, mitochondrial health, and metabolic regulation.

KPV / GHK-CU

## Dermal

Advanced topical anti-inflammatory and cellular skin rejuvenation.

# Current Product Portfolio



Daily Energy & Vitality Support

**Ageless** —

Powered by Epitalon Peptides + NMN



Focus, Memory & Mental Energy

**Blue** —

Powered by Methylene Blue



Muscle, Joint & Gut Support

**BPC** —

Powered by BPC-157 Peptides



Relaxation, Sleep & Stress Relief

**Chill** —

Powered by Pinealon Peptides + DHH-B



Gut Balance & Recovery Support

**KPV** —

Powered by KPV Peptides



Scalp Health & Follicle Support

**Hair** —

Powered by Copper Tripeptide-1 (GHK-CU Peptides) + Zinc Thymulin + PTD-DBM + DMSO



Hydration, Elasticity & Radiance

**Skin** —

Powered by Acetyl Hexapeptide-8 + Pentapeptide-18 + GHK-Cu (Copper Peptides)

# The Window of Opportunity.

A rare convergence of timing and technology, creating an inflection point that simply didn't exist five years ago, and unlocking a category of opportunity that is only now becoming investable at scale.



## GLP-1 Breakthrough

Drugs like Ozempic and Wegovy have normalized peptide-based solutions globally

## Consumer Behavior Shift

From traditional reactive healthcare → proactive optimization

## Cultural Acceleration

No consumer-friendly format has successfully unlocked mass adoption

## Major Delivery Gap

Mainstream platforms and media driving awareness at scale

### Conclusion:

*We are entering at the exact moment the market becomes inevitable.*



# Operating at the **Intersection.**

We are perfectly positioned at the convergence of three hyper-growth, multi-billion-dollar macro-trends.

**\$140B+\***

## **Peptide Therapeutics**

Riding the mass awareness created by GLP-1s and Semaglutide.

**\$209B+\***

Capturing the transition from traditional supplements to advanced bio-compounds.

**\$500B+\***

Meeting the demand for optimization and biological age reduction.



We are giving a **billion-dollar** market an alternative, innovative delivery system

\*\$140B: [Peptide Therapeutics Market Summary](#) | \*\$209B: [Dietary Supplements Market Summary](#) | \*\$500B: [Global Wellness Institute](#)



# Business Model.

Biotech margins at consumer scale.

## Revenue Architecture

- **Direct-to-Consumer (DTC):** High-margin, direct relationship minimizing CAC over time.
- **Subscription Engine:** Built for repeat customers via a sticky daily-use regimen (30-day patch supplies).
- **Omnichannel Retail:** Expanding our existing store footprint to more doors.
- **Future IP Horizons:** B2B licensing of our transdermal delivery matrix.

## The Strategic Moat

- **Brand Defensibility:** Establishing clinical-grade trust in an unregulated, fragmented consumer category.
- **Unit Economics:** Extremely high lifetime value (LTV) relative to acquisition costs.

# Pangea Wellness Foods

We have already validated our operational ability to formulate, manufacture, and scale high-margin health products in tier-1 retail.

- **Regulatory & Supply Chain:** CFIA & FDA certified production facilities actively online.
- **Brand Execution:** Proven ability to design consumer-ready packaging that commands premium shelf space.



# Market Comparables.

Defining the valuation paradigm for a hybrid consumer-health platform.

COMPANY	CATEGORY STRATEGY	STATUS / TICKER	VALUATION
<b>Hims &amp; Hers Health</b>	Consumer Platform & Telehealth	NYSE: HIMS	~\$4.5B – \$6B
<b>Ro (Roman)</b>	Consumer Platform & Digital Health	Private	~\$5B+
<b>AgelessRx</b>	Longevity Platform & Peptide Distribution	Private	Est. \$100M – \$300M
<b>Transcend Company</b>	Hormone & Peptide Optimization Platform	Private	Est. \$100M – \$250M

*The Precision Peptide Company uniquely bridges the gap between massive Pharma IP valuations and high-growth Consumer Health platforms.*



# Management & Executive Team.

The people driving innovation across Precision Peptide and Amino Innovations have decades of experience in food manufacturing, biotechnology, and business development.

---

## **Pratap Sandhu**

Chief Executive Officer

A visionary entrepreneur with deep roots in food manufacturing, Pratap transformed his family's business from a small operation to a global success. With his BCIT background in marketing and professional sales, he leads Pangea's strategic direction and growth initiatives.

## **Matt Stang**

Co-Founder, Chief Visionary Officer

Built High Times into a cultural icon, driving cannabis normalization and creating platforms that reshaped the industry. Brings deep experience in brand building and market creation.

## **Nashir Virani**

Director

Food industry pioneer and former CEO of Golden Boy Foods, which he grew from a coffee business to a diversified food manufacturer before its US\$500 million acquisition by Kraft in 2015. Currently CEO of First Choice Foods, Nashir brings invaluable industry expertise.

## **Justin Kirkland**

Co-Founder, Chief Scientific Officer

A longevity medicine expert with 30+ years in drug development and pharmaceutical innovation. A patent holder and founder of multiple pharmaceutical companies.

## **Ajit Bhatti**

Director

A technology and investment veteran with 19 years of leadership experience, Ajit specializes in large-scale project implementation and venture capital investments. His expertise spans healthcare, technology, and mineral exploration.

## **Barbara Branaman**

Co-Founder, Principal Innovator

Co-founded BioReset Medical, leading growth in regenerative care with deep expertise in operations and health innovation.

# Investor Information.

Stock Listing

CSE: BPC

OTCQB: PNGAF

---

<b>Basic Outstanding:</b>	<b>43,569,607</b>
---------------------------	-------------------

---

<b>Warrants:</b>	<b>8,396,600</b>
------------------	------------------

---

<b>Options:</b>	<b>2,733,333</b>
-----------------	------------------

---

<b>Fully Diluted:</b>	<b>54,699,540</b>
-----------------------	-------------------

---

<b>52 Week High-Low</b>	<b>\$0.52- \$0.175</b>
-------------------------	------------------------

### **Disclaimer:**

This presentation contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, "forward-looking statements"). All statements on this website, other than statements of historical fact, are forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to: the Company's corporate objectives, business strategy, and long-term aspirations, including its mission to expand access to next-generation peptide technologies; the Company's research and development activities relating to its peptide-based formulations and drug delivery platforms, including its advanced transdermal and oral delivery systems; the anticipated applications and benefits of the Company's peptide products and technologies;

the Company's plans to expand and scale its distribution network across North American clinical, consumer, and performance-driven markets; the anticipated market opportunity in the North American peptide-based wellness industry, including statements regarding the growth of the peptide segment; the Company's plans to enter into licensing, partnership, collaboration, manufacturing, or other commercial agreements in connection with its products and delivery platforms; the Company's plans with respect to future financing and the anticipated use of proceeds therefrom; expectations regarding revenues, expenses, and future financial performance; and any other information as to the future plans and outlook for the Company.

Forward-looking statements are frequently identified by words and phrases such as "aims," "anticipates," "believes," "continues to," "designed for," "estimates," "expects," "focused on," "forecasts," "future," "guidance," "in development," "intends," "may," "might," "objective," "outlook," "plans," "potential," "projected," "pursue," "reimagined," "scheduled," "seeks," "should," "strategy," "targets," "will," "will be achieved," "will occur," or variations of such words and expressions, or statements that certain actions, events, or results "could," "would," or "might" occur. Forward-looking statements are based on the current expectations, estimates, assumptions, and beliefs of management as of the date the relevant statement is made and are necessarily subject to a number of risks, uncertainties, and other factors.

Forward-looking statements are not guarantees of future performance. They involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation: the early-stage nature of the Company's product development activities, including the transdermal delivery platform currently under development, and the inherent uncertainties associated therewith; the ability to obtain, maintain, and enforce any patents or other intellectual property rights in respect of the Company's product formulations and delivery technologies;

competition from other companies with greater resources, more established distribution networks, and more advanced product pipelines in the peptide wellness and biopharmaceutical sectors; the ability to scale the Company's distribution network across North America as anticipated and to respond to changes in consumer demand for peptide-based wellness solutions; the potential for adverse regulatory action in Canada, the United States, or other applicable jurisdictions in respect of the Company's peptide products, including actions by Health Canada, the U.S. Food and Drug Administration, or the Federal Trade Commission relating to product classification, health claims, or advertising practices; changes in laws and regulations applicable to natural health products, consumer wellness products, drug development, and advertising; the availability of financing on acceptable terms, or at all, to fund the Company's operations, product development, and distribution expansion; the impact of general economic and market conditions, including inflation and interest rate fluctuations, on consumer demand for wellness products;

reliance on third-party contract manufacturers, researchers, distributors, and other service providers;

risks associated with peptide synthesis and manufacturing scale-up, including challenges in maintaining purity, potency, and identity across production batches; foreign exchange fluctuations, given the Company's operations and market focus across Canada and the United States; and other risk factors described in the Company's public filings available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

The above list of risk factors is not exhaustive. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements.

Readers and investors are cautioned not to place undue reliance on forward-looking statements, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements contained on this website are made as of the date this website was published and are expressly qualified in their entirety by this cautionary note. Except as required by applicable Canadian securities laws or the policies of the Canadian Securities Exchange, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.



The  
Precision  
Peptide  
Company

The Future is. *Here*

CSE: BPC | OTCQB: PNGAF

---

[pratap@precisionpeptidecompany.com](mailto:pratap@precisionpeptidecompany.com)